AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03613493 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HPV self-sampling kit
Description: The HPV self-sampler kit will include the collection swab and the vial for collecting and storing the specimen, and an instructional sheet that visually depicts the steps for self-sampling.
Study NCT03613493 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV self-sampling kit
Description: The HPV self-sampler kit will include the collection swab and the vial for collecting and storing the specimen, and an instructional sheet that visually depicts the steps for self-sampling.
Study NCT03613493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally-targeted Fear Appeal Message
Description: Participants will receive culturally-targeted and fear appeal messages in a graphically designed kit.
Study NCT03613493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear Appeal Message
Description: Participants will receive fear appeal messages (only) in a graphically designed kit.
Study NCT03613493 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interview
Description: Participants will be interviewed about experiences using the self-sampling tool (qualitative).
Study NCT02091700 — intervention group
Intervention type: OTHER
Intervention: Indocyanine Green ICG
Study NCT02431598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gadoxetate disodium
Study NCT02431598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gadoterate dimeglumine
Study NCT02431598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Study NCT04474483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
Study NCT04474483 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Methylcellulose) capsule
Description: Placebo capsules will be prepared with opaque gelatin capsules, filled using methylcellulose and over-encapsulated to appear identical to interventional drug. Placebo capsules will be given orally in the same regimen as intervention (three times daily for 14 days). Capsules will be prepared by the research pharmacist and will be mailed to study subjects directly by courier. Placebo capsules will be stored at room temperature.
Study NCT00424242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Orally beginning at 500 mg/m2 every 3 weeks until disease progression
Study NCT00023231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: 1 mg/kg/dose at study entry and Weeks 2, 4, 6, and 8
Study NCT00023231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone/prednisone
Description: Dosage is dependent on weight and varies throughout study. Refer to protocol for more information.
Study NCT01195948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule with no active ingredients to mimic B27PD
Study NCT00023231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Solution or oral tablet taken daily. Dosage depends on body surface area.
Study NCT00023231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Oral tablet taken once prior to transplant. Dosage dependent on body surface area.
Study NCT00023231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bactrim
Description: Oral tablet taken three times per week. Dosage is dependent on weight.
Study NCT00023231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Oral tablet taken daily. Dosage is dependent on weight.
Study NCT00023231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor
Description: Oral tablet taken daily
Study NCT02023489 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 1H/ 13C and 31P Magnetic Resonance Spectroscopy
Description: Study participants will be studied in the fasting state after an overnight fast of at least 10 h. Participants will arrive at the MR-Centre in the morning of the study. Between 6:30 and 10:00 a.m., 1H MRI (3T) will be performed for the assessment abdominal adipose tissue distribution and composition as well as myocardial functional parameters. 1H/13C MRS examinations (7T) will be performed for measurements of myocardial, skeletal muscle and liver lipid content and composition as well as glycogen content. Additionally, ATP synthesis and energy metabolism will be assessed.
Study NCT02023489 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Meal Tolerance Test
Description: A meal tolerance test meal tolerance test according to Petersen et al. (PNAS, Vol 104, 2007) will be performed. After MRI and MRS examinations subjects will be returned at our outpatients clinic, where small polyethylene catheter will be inserted in an antecubital vein for hourly blood sampling. At 10:30 a.m. and 1:30 p.m. two liquid high carbohydrate meals of equal size containing all the required daily energy (30 kcal/kg of body weight; 55% carbohydrate, 10% protein, and 35% fat) with an additional 25% of the daily energy requirements added in the form of sucrose will be served.~At 5 p.m. subjects will be returned at the MR - Centre for postprandial 1H / 13C MRS (7T) of muscle, liver and myocardial lipid and glycogen contents. Myocardial function parameters and abdominal fat distribution will be assessed again by 1H MRI (3T).
Study NCT02023489 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperglycemic-hyperinsulinemic clamp
Description: All volunteers will be admitted in the morning and basal 13C tracer enrichment will be assessed.~At 8:00a.m. (0 min) a hyperglycemic-hyperinsulinemic-pancreatic clamp test will be initiated by somatostatin (-5-300 min: 0.1 µg·kg-1·min-1, UCB Pharma, Vienna, Austria) and insulin (0 - 8 min: 80 mU·min-1·m-2 body surface area; 8 -300 min: 40 mU·min-1·m-2 body surface area) infusion. Plasma glucose will be raised and maintained at \~180 mg·dL-1 by primed (0.2 g·kg-1)-variable dextrose infusion (20%w/v) enriched with \[1-13C\]glucose (40%w/w). A second catheter will be placed into an antecubital vein of the other arm and blood samples for the measurement of glucose, insulin and c-peptide. Glucose concentrations will be analysed immediately every 5 minutes, employing a glucose analyser. Myocardial glycogen concentrations will be measured before the clamp (-60 - 0 min) and from 90 min to 180 min during the clamp employing 13C MRS.
Study NCT01835106 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural catheter is used postoperatively
Study NCT01835106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment catheter is used postoperatively
Study NCT02643693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P3L
Description: Ad libitum use for a maximum of three hours.~P3L delivers, on average, 80 µg of nicotine per puff under Health Canada Intense smoking regime.
Study NCT02643693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VUSE
Description: Ad libitum use for a maximum of three hours.~VUSE delivers, on average, 80 µg of nicotine per puff based on the CORESTA e-cigarette recommended smoking regime.
Study NCT02643693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CC
Description: Ad libitum use of the subject's own brand of non-menthol CC for a maximum of three hours.
Study NCT00526617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888
Description: Oral capsules
Study NCT00526617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral capsules
Study NCT00962286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.Intravenous catheters will be placed in each upper limb for infusion of clearance markers and blood sampling.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered. Thereafter, inulin and p-aminohippuric acid will be infused continuously. A 200-300 ml water load will be given during the first 60-min prime.~Subjects will be started on furosemide p.o. 20 mg every 12 hours, starting on day 1 at 15.00 after the renal function studies. Nine doses will be taken, the last dose on day 4 at 7 am.~In case the blood pressure does not decrease following 20 mg bid furosemide administration, the study will be repeated after 4 weeks using a dose of 40 mg p.o. bid.
Study NCT04487990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unfractionated Heparin
Description: Addition of unfractioned heparin to CVVHD system already running under citrate regional anticoagulation.
Study NCT02774317 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasma
Description: FFP (plasma frozen within 8 hrs of collection) or FP24 (plasma frozen within 24 hrs of collection)
Study NCT02774317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma
Description: FFP (plasma frozen within 8 hrs of collection) or FP24 (plasma frozen within 24 hrs of collection)
Study NCT00787878 — intervention group
Intervention type: DRUG
Intervention: somatropin
Description: SGA previously treated with Norditropin®
Study NCT00787878 — intervention group
Intervention type: DRUG
Intervention: No treatment given
Description: Untreated SGA
Study NCT00787878 — intervention group
Intervention type: DRUG
Intervention: No treatment given
Description: AGA (Average gestational age)
Study NCT03261999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Mesylate
Description: Subcutaneous injection of 25mg Leuprolide Mesylate
Study NCT01021397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHPIV3cp45
Description: 10\^5 TCID50 nasal drops
Study NCT01021397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rHPIV3cp45 placebo
Description: 1X-L15 nasal drops
Study NCT04868669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-home, intensive nutrition counseling
Description: * Individualized sessions will be conducted by trained health workers following a standard document (counseling booklet)~* The messages to be provided through the counseling will be contextualized~* Sessions will start from the early second trimester and repeat monthly until 36 weeks of gestation~* Counseling sessions will be conducted at the participant's place~* Sessions will involve influential family members such as the husband, mother-in-law, mother, and the household head along with the pregnant women~* Women will receive personalized feedback on their dietary intake pattern (dietary diversity) and the rate of weight gain in each session~* Sessions will be tailored according to each participant's need and progress
Study NCT03835039 — intervention group
Intervention type: DEVICE
Intervention: NIRS
Description: Monitoring cerebral and perirenal perfusion using NIRS
Study NCT04737525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant placement, bone and soft tissue augmentation on buccal site
Description: 1. Atraumatic extraction~2. Palatinal positioning of tapered implant (BLX) 3.75mm diameter~3. 3-4 mm below vestibular gingival line or 1 mm below bone crest~4. Implant placement~5. Allogenic bone packing of the jumping distance and soft tissue grafting~6. Connective tissue graft (CTG) or porcine-derived membrane~7. Provisional restoration out of occlusion and mandibular movements~8. X-ray
Study NCT02963480 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac Surgery
Study NCT01168895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipro Inhale (Ciprofloxacin, BAYQ3939)
Description: 32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
Study NCT01168895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipro Inhale (Ciprofloxacin, BAYQ3939)
Description: 48.75 mg ciprofloxacin corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
Study NCT00313235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC Vaccine and Cyclophosphamide
Description: Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10\^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure.
Study NCT03457857 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cleanser
Description: Cosmetic Baby Cleanser/Shampoo
Study NCT03457857 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cleanser and Lotion
Description: Cosmetic Baby Cleanser/Shampoo and Baby Lotion
Study NCT02674516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Study NCT02674516 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Study NCT00229671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey 1
Description: During the initial survey, we reviewed dispensed medications by having parents of patients with prescriptions under 21 read the medication label. We then asked questions about potential side effects, method of medication administration, communication regarding the medication with the pharmacist and the health care provider, and demographic information. Research assistants underwent several weeks of training to ensure a standardized approach to surveys.
Study NCT00229671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey 2
Description: If the parent completed the initial survey, we attempted a second survey 2 months after the index visit to capture persistent symptoms. Surveys were translated and back translated into Spanish and Cambodian and conducted by fluent bilingual interviewers. Surveys were pretested and revised based on 2 focus groups of parents representing a broad array of socioeconomic backgrounds.
Study NCT02838745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT02838745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT03194334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Study NCT03194334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: 1g creatine/day
Study NCT03194334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: pills
Study NCT03194334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine
Description: 0.8g beta-alanine per day
Study NCT01292408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochloroquine
Description: 800 mg per os once, and then 400 mg per day
Study NCT00518570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam was started at 250 mg qhs at the end of the first week of the follicular phase. Dose was gradually increased up to 1500 mg bid as tolerated or clinically effective. The treatment phase lasted 4 months.
Study NCT02251353 — intervention group
Intervention type: PROCEDURE
Intervention: intervention
Description: hepatic and/or pulmonary resection, radiofrequency ablation (RFA), transcatheter arterial chemoembolization, CyberKnife stereotactic radiosurgery
Study NCT02251353 — intervention group
Intervention type: DRUG
Intervention: systemic treatment
Description: Systemic therapy
Study NCT02455128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic listening
Description: Method of responding to others in order to encourage better communication and clearer understanding of personal concerns.
Study NCT00875316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cogane™ (PYM50028)
Description: Orally active neurotrophic factor inducer
Study NCT01308619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning
Study NCT01308619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, oral, one capsule daily in the morning
Study NCT00038766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semapimod
Description: semapipmod 60 mg IV x 5 days
Study NCT00038766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semapimod
Description: IV 30 mg x 5 days
Study NCT00038766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo IV
Study NCT03846934 — intervention group
Intervention type: DEVICE
Intervention: Ultrasonography thoracic
Description: Thoracic ultrasonography will be performed as soon as possible after admission to the ED, without delaying the start of treatment and in addition to routine thoracic radiography.
Study NCT00888875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel
Description: insertion after induction of anaesthesia. Afterwards, intubation over the device fiberoptically
Study NCT00888875 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ILMA
Description: Insertion after Induction. Insertion of tracheal tube over device
Study NCT03609463 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Small change intervention
Description: The small change intervention is a behavioral intervention to help people gradually lose weight by making small changes in their lifestyle. At the beginning of the intervention participants will be met in person to be guided in setting an eating and a physical activity goal. Participants will be then contacted through the phone or met in person weekly for 3 months to check on their adherence to the selected goals and to discuss about facilitators and barriers to goal completion, in order to increase their motivation and problem solving skills. Every weekly contact will last about an hour and will be administered in an individual setting. At each contact selected goals can be revised, changed or another goal can be added based on levels of adherence.
Study NCT03609463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small change intervention
Description: The small change intervention is a behavioral intervention to help people gradually lose weight by making small changes in their lifestyle. At the beginning of the intervention participants will be met in person to be guided in setting an eating and a physical activity goal. Participants will be then contacted through the phone or met in person weekly for 3 months to check on their adherence to the selected goals and to discuss about facilitators and barriers to goal completion, in order to increase their motivation and problem solving skills. Every weekly contact will last about an hour and will be administered in an individual setting. At each contact selected goals can be revised, changed or another goal can be added based on levels of adherence.
Study NCT03609463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-being intervention
Description: The well-being intervention is a coaching intervention aimed at motivating people in making lifestyle changes by reducing levels of stress through the promotion of psychological well-being. It will consists in 4 weekly sessions to be held before starting the small change intervention. Each session will last about an hour and will be administered in an individual setting.
Study NCT03609463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The treatment as usual includes any recommendation given to the participants by their physicians, including diet, physical activity, medication and glycemic control instructions.
Study NCT03609463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: The treatment as usual includes any recommendation given to the participants by their physicians, including diet, physical activity, medication and glycemic control instructions.
Study NCT04233853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CoLiPri intervention
Description: General practitioners and their screened patients have access to the consultation-liaison services for a total duration of 12 months, including standard screening, expert consultations, on demand patient referral for structured mental health diagnostics, psychoeducation and treatment planning, as well as brief psychotherapeutic intervention and triage.
Study NCT04233853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual primary care enhanced
Description: Usual primary care practice as offered in routine care. Enhanced means that practitioners receive a basic training which consists of guideline-based structured screening procedures for depression and anxiety mental disorders in primary care.
Study NCT04233853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual primary care enhanced
Description: Usual primary care practice as offered in routine care. Enhanced means that practitioners receive a basic training which consists of guideline-based structured screening procedures for depression and anxiety mental disorders in primary care.